Common Stock (QB) Stock Price

0.00 (0.0%)
Volume 53
Bid Price 5.00
Ask Price 6.00
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Common Stock (QB) QSAM OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 6.00 09:30:10
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
1 53 - 0.14 - 9.00
Last Trade Time Type Quantity Stock Price Currency
09:39:56 53 $ 5.25 USD


Draw Mode:

Common Stock (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 10.12M 1.69M 302.05k $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
826.00 $ - - - -

more financials information »

Common Stock (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical QSAM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.,9601.7440.85%
1 Month6.506.504.206.141,215-0.50-7.69%
3 Months0.,8995.802,900.0%
6 Months0.2859.000.140.363544125,1365.722,005.26%
1 Year0.379.000.140.352192526,1775.631,521.62%
3 Years0.,5655.802,900.0%
5 Years0.,5655.802,900.0%

Common Stock (QB) Description

QSAM Bioscience, Inc. is developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam), for the treatment of bone cancer and related diseases. The FDA recently cleared QSAM's IND to commence Phase 1 clinical trials, and approved the company's application for Orphan Drug Designation for the indication of osteosarcoma, a devastating form of bone cancer that affects mainly children. QSAM is led by an experienced executive team and Board of Directors that have completed dozens of FDA approvals and multiple successful biotech exits. CycloSam has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam.

Your Recent History
Common Sto..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.